After one month on semaglutide, you may expect significant appetite suppression, controlled blood sugar levels, loss of fat mass, and weight changes
When you eat less, you lose weight
The science of slowed gastrointestinal motility GLP-1 receptor agonists act on the gutbrain axis and are known to slow gastric emptying and overall gastrointestinal transit , contributing to early satiety and appetite suppression. As intestinal transit slows, the colon has more time to absorb water from stool , leading to hard, dry stools that are difficult to pass . Constipation is a common, dose-related adverse effect listed in FDA prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide) and is most frequently reported during dose escalation , with improvement over time., Step-by-Step MD Protocol for Relief 1
Are side effects worse with one or the other
Eur J Heart Fail (2019) 21(10):12708